US8153602B1
(en)
*
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
GB9514435D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Danisco |
Inhibition of gene expression
|
US5652356A
(en)
*
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
US7074768B2
(en)
|
1995-08-17 |
2006-07-11 |
Idera Pharmaceuticals, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
US6624293B1
(en)
|
1995-08-17 |
2003-09-23 |
Hybridon, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
GB9519299D0
(en)
|
1995-09-21 |
1995-11-22 |
Farrar Gwyneth J |
Genetic strategy
|
GB9604449D0
(en)
*
|
1996-03-01 |
1996-05-01 |
Farrar Gwyneth J |
Genetic strategy ii
|
US8551970B2
(en)
|
1996-04-02 |
2013-10-08 |
Optigen Patents Limited |
Genetic suppression and replacement
|
GB9606961D0
(en)
|
1996-04-02 |
1996-06-05 |
Farrar Gwyneth J |
Genetic strategy III
|
US20030036519A1
(en)
*
|
1998-04-21 |
2003-02-20 |
Ryszard Kole |
Stable alteration of pre-mrna splicing patterns by modified rnas
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
JP2000325085A
(ja)
|
1999-05-21 |
2000-11-28 |
Masafumi Matsuo |
デュシェンヌ型筋ジストロフィー治療剤
|
US6677445B1
(en)
|
1999-08-27 |
2004-01-13 |
Chiron Corporation |
Chimeric antisense oligonucleotides and cell transfecting formulations thereof
|
CA2400573A1
(en)
*
|
2000-03-28 |
2001-10-04 |
Isis Pharmaceuticals Inc. |
Alteration of cellular behavior by antisense modulation of mrna processing
|
US6653467B1
(en)
|
2000-04-26 |
2003-11-25 |
Jcr Pharmaceutical Co., Ltd. |
Medicament for treatment of Duchenne muscular dystrophy
|
WO2001083740A2
(en)
|
2000-05-04 |
2001-11-08 |
Avi Biopharma, Inc. |
Splice-region antisense composition and method
|
US6727355B2
(en)
|
2000-08-25 |
2004-04-27 |
Jcr Pharmaceuticals Co., Ltd. |
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
|
EP1191097A1
(en)
*
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
GB2382577A
(en)
*
|
2001-11-28 |
2003-06-04 |
Talat Nasim |
A reporter-based assay for assessing relative RNA processing activity in mammaliian cells
|
WO2004083432A1
(en)
|
2003-03-21 |
2004-09-30 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
AU2004262853B2
(en)
|
2003-07-17 |
2008-06-05 |
Upfield Europe B.V. |
Process for the preparation of an edible dispersion comprising oil and structuring agent
|
US20050234002A1
(en)
|
2004-01-23 |
2005-10-20 |
Mourich Dan V |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
WO2005094370A2
(en)
|
2004-03-29 |
2005-10-13 |
The General Hospital Corporation |
Oligonucleotide complex compositions and methods of use as gene alteration tools
|
HUE028632T2
(en)
|
2004-06-28 |
2016-12-28 |
Univ Western Australia |
To skip an antisense oligonucleotide exon and use it for procedures
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
US7879992B2
(en)
|
2005-01-31 |
2011-02-01 |
Isis Pharmaceuticals, Inc. |
Modification of MyD88 splicing using modified oligonucleotides
|
EP1855694B1
(en)
|
2005-02-09 |
2020-12-02 |
Sarepta Therapeutics, Inc. |
Antisense composition for treating muscle atrophy
|
WO2006087092A2
(en)
|
2005-02-17 |
2006-08-24 |
Unilever N.V. |
Fat granules
|
NZ562780A
(en)
*
|
2005-04-29 |
2010-03-26 |
Univ North Carolina |
Method and compositions for regulated expression of nucleic acid at post-transcriptional level
|
ES2397113T3
(es)
|
2005-06-23 |
2013-03-04 |
Isis Pharmaceuticals, Inc. |
Composiciones y procedimientos para modular el corte y empalme de SMN2
|
WO2007028065A2
(en)
|
2005-08-30 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
WO2007047913A2
(en)
|
2005-10-20 |
2007-04-26 |
Isis Pharmaceuticals, Inc |
Compositions and methods for modulation of lmna expression
|
US7785834B2
(en)
*
|
2005-11-10 |
2010-08-31 |
Ercole Biotech, Inc. |
Soluble TNF receptors and their use in treatment of disease
|
KR20170119730A
(ko)
*
|
2005-11-10 |
2017-10-27 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
Tnf 수퍼패밀리 수용체에 대한 스플라이스 스위칭 올리고머 및 질환 치료에 있어서의 그의 용도
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
PL2049664T3
(pl)
|
2006-08-11 |
2012-02-29 |
Biomarin Tech Bv |
Jednoniciowe oligonukleotydy komplementarne do powtarzalnych elementów do leczenia chorób genetycznych związanych z niestabilnością powtórzeń DNA
|
US20090264353A1
(en)
*
|
2007-10-19 |
2009-10-22 |
Santaris Pharma A/S |
Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
|
AU2008262391A1
(en)
|
2007-06-06 |
2008-12-18 |
Avi Biopharma, Inc. |
Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
|
CN101790385A
(zh)
*
|
2007-07-12 |
2010-07-28 |
普罗森那技术公司 |
用于使化合物靶向多种选定器官、组织或肿瘤细胞的分子
|
CA2704049A1
(en)
|
2007-10-26 |
2009-04-30 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
WO2009064920A2
(en)
*
|
2007-11-13 |
2009-05-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
TR201902952T4
(tr)
|
2008-10-24 |
2019-03-21 |
Sarepta Therapeutics Inc |
Dmd için ekson atlama bileşimleri.
|
KR101829469B1
(ko)
|
2008-12-04 |
2018-03-30 |
큐알엔에이, 인크. |
Epo에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(epo) 관련된 질환의 치료
|
WO2010065787A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
KR101761424B1
(ko)
|
2008-12-04 |
2017-07-26 |
큐알엔에이, 인크. |
Vegf에 대한 천연 안티센스 전사체의 억제에 의해 맥관 내피 성장 인자(vegf) 관련된 질환의 치료
|
EP2393825A2
(en)
|
2009-02-06 |
2011-12-14 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
CN102387817B
(zh)
|
2009-02-12 |
2018-01-30 |
库尔纳公司 |
通过抑制针对脑衍生神经营养因子(bdnf)的天然反义转录物来治疗bdnf相关的疾病
|
WO2010107733A2
(en)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
US9708604B2
(en)
|
2009-03-17 |
2017-07-18 |
Curna, Inc. |
Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
|
EP2421971B1
(en)
|
2009-04-24 |
2016-07-06 |
BioMarin Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
US9155754B2
(en)
|
2009-05-06 |
2015-10-13 |
Curna, Inc. |
Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
|
US20120046236A1
(en)
|
2009-05-06 |
2012-02-23 |
Opko Curna Llc |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
KR101742334B1
(ko)
|
2009-05-08 |
2017-06-01 |
큐알엔에이, 인크. |
Dmd 패밀리에 대한 천연 안티센스 전사체의 억제에 의한 디스트로핀 패밀리 관련된 질환의 치료
|
DK2432881T3
(en)
|
2009-05-18 |
2018-02-26 |
Curna Inc |
TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
|
CA2762987A1
(en)
|
2009-05-22 |
2010-11-25 |
Joseph Collard |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
CN103221541B
(zh)
|
2009-05-28 |
2017-03-01 |
库尔纳公司 |
通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
|
WO2010148065A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
CA2765700C
(en)
|
2009-06-16 |
2021-01-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
PT3305302T
(pt)
|
2009-06-17 |
2018-12-14 |
Biogen Ma Inc |
Composições e métodos de modulação de excisões de smn2 em um sujeito
|
EP2446036B1
(en)
|
2009-06-24 |
2017-03-01 |
CuRNA, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
US8921330B2
(en)
|
2009-06-26 |
2014-12-30 |
Curna, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
US20120252869A1
(en)
|
2009-07-24 |
2012-10-04 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
JP6128848B2
(ja)
|
2009-08-05 |
2017-05-17 |
クルナ・インコーポレーテッド |
インスリン遺伝子(ins)に対する天然アンチセンス転写物の抑制によるインスリン遺伝子(ins)関連疾患の治療
|
CN102625841A
(zh)
|
2009-08-11 |
2012-08-01 |
欧科库尔纳有限责任公司 |
通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
|
CN102482670B
(zh)
|
2009-08-21 |
2018-06-15 |
库尔纳公司 |
通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
|
US9023822B2
(en)
|
2009-08-25 |
2015-05-05 |
Curna, Inc. |
Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
|
ES2664591T3
(es)
|
2009-09-25 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG
|
EE05711B1
(et)
*
|
2009-10-07 |
2014-04-15 |
Tartu Ülikool |
Meetod ja kompositsioon konditsionaalselt letaalsete viirusmutantide loomiseks ja eukarootse raku elulisuse k?rvaldamiseks
|
KR20230137491A
(ko)
|
2009-11-12 |
2023-10-04 |
더 유니버시티 오브 웨스턴 오스트레일리아 |
안티센스 분자 및 이를 이용한 질환 치료방법
|
DK2513310T3
(en)
|
2009-12-16 |
2018-02-05 |
Curna Inc |
TREATMENT OF DISEASES CONNECTED WITH MEMBRANE-BONDED TRANSCRIPTION FACTOR Peptidase, site 1 (MBTPS1), BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MBTPS1
|
DK2516648T3
(en)
|
2009-12-23 |
2018-02-12 |
Curna Inc |
TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF
|
RU2619185C2
(ru)
|
2009-12-23 |
2017-05-12 |
Курна, Инк. |
Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
|
CA2785451C
(en)
|
2009-12-24 |
2019-01-22 |
Prosensa Technologies B.V. |
Molecule for treating an inflammatory disorder
|
US8962585B2
(en)
|
2009-12-29 |
2015-02-24 |
Curna, Inc. |
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
JP5993744B2
(ja)
|
2009-12-29 |
2016-09-14 |
カッパーアールエヌエー,インコーポレイテッド |
核呼吸因子1(nrf1)に対する天然アンチセンス転写物の阻害による核呼吸因子1関連疾患の治療
|
CN102791862B
(zh)
|
2009-12-31 |
2017-04-05 |
库尔纳公司 |
通过抑制胰岛素受体底物2(irs2)和转录因子e3(tfe3)的天然反义转录物而治疗irs2相关疾病
|
WO2011082409A2
(en)
|
2010-01-04 |
2011-07-07 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
|
EP2521785B1
(en)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases
|
ES2664866T3
(es)
|
2010-01-11 |
2018-04-23 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
|
RU2611192C2
(ru)
|
2010-01-25 |
2017-02-21 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療
|
ES2657969T3
(es)
|
2010-04-02 |
2018-03-07 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el Factor 3 estimulante de colonias (CSF3) por inhibición del transcrito antisentido natural a CSF3
|
US9044494B2
(en)
|
2010-04-09 |
2015-06-02 |
Curna, Inc. |
Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
KR101915115B1
(ko)
|
2010-05-03 |
2018-11-05 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
ES2664572T3
(es)
|
2010-05-26 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el homólogo atonal 1 (ATOH1) mediante inhibición del transcrito antisentido natural a ATOH1
|
EP2576784B1
(en)
|
2010-05-26 |
2017-11-15 |
CuRNA, Inc. |
Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
|
EP2584907B1
(en)
|
2010-06-22 |
2014-04-23 |
Unilever NV |
Edible fat powders
|
CN103025873B
(zh)
|
2010-06-23 |
2018-05-08 |
库尔纳公司 |
通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
|
CA2805318A1
(en)
|
2010-07-14 |
2012-01-19 |
Curna, Inc. |
Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
|
WO2012047956A2
(en)
|
2010-10-06 |
2012-04-12 |
Opko Curna Llc |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
CN103180445B
(zh)
|
2010-10-22 |
2018-02-16 |
库尔纳公司 |
通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
WO2012065143A1
(en)
|
2010-11-12 |
2012-05-18 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
CN103459599B
(zh)
|
2010-11-23 |
2017-06-16 |
库尔纳公司 |
通过抑制nanog的天然反义转录物而治疗nanog相关疾病
|
EP2651234B1
(en)
|
2010-12-17 |
2015-01-21 |
Unilever N.V. |
Process of compacting a microporous fat powder and compacted fat powder so obtained
|
CA2820360C
(en)
|
2010-12-17 |
2018-10-30 |
Unilever Plc |
Edible water in oil emulsion
|
EP2717913A4
(en)
|
2011-06-08 |
2014-11-26 |
Univ Indiana Res & Tech Corp |
MONOCLONAL ANTIBODIES AND ANTIGENS FOR DIAGNOSING AND TREATING PULMONARY DISEASE AND INJURY
|
CA2838588C
(en)
|
2011-06-09 |
2021-09-14 |
Curna, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
BR112014005234A2
(pt)
|
2011-09-06 |
2017-04-11 |
Curna Inc |
tratamento de doenças relacionadas com subunididades alfa dos canais de sódio dependentes de voltagem (scnxa) com pequenas moléculas
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
US20150025231A1
(en)
|
2012-01-11 |
2015-01-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for modulation of ikbkap splicing
|
NZ627896A
(en)
|
2012-01-27 |
2016-11-25 |
Biomarin Technologies B V |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
HUE040179T2
(hu)
|
2012-03-15 |
2019-02-28 |
Curna Inc |
Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
|
JP2015523854A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Smn遺伝子ファミリー発現を調節するための組成物及び方法
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
EP2850190B1
(en)
|
2012-05-16 |
2020-07-08 |
Translate Bio MA, Inc. |
Compositions and methods for modulating mecp2 expression
|
EP3103872B1
(en)
|
2012-07-12 |
2018-08-29 |
ProQR Therapeutics II B.V. |
Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell
|
CN111440796A
(zh)
|
2012-12-20 |
2020-07-24 |
萨雷普塔医疗公司 |
用于治疗肌营养不良症的改良的外显子跳跃组合物
|
EP2943225A4
(en)
|
2013-01-09 |
2016-07-13 |
Ionis Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR MODULATING SMN2 DISTRIBUTION IN THE BODY OF A PATIENT
|
AU2014236160A1
(en)
|
2013-03-14 |
2015-10-01 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
CN117844807A
(zh)
|
2013-03-14 |
2024-04-09 |
萨勒普塔医疗公司 |
用于治疗肌营养不良的外显子跳跃组合物
|
EP3662912A1
(en)
|
2013-03-15 |
2020-06-10 |
Sarepta Therapeutics, Inc. |
Improved dosages of eteplirsen for treating duchenne muscular dystrophy
|
US10590412B2
(en)
|
2013-04-19 |
2020-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
US10174328B2
(en)
|
2013-10-04 |
2019-01-08 |
Translate Bio Ma, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
WO2015161170A2
(en)
|
2014-04-17 |
2015-10-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of smn2 splicing in a subject
|
GB201410693D0
(en)
*
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
JP6867945B2
(ja)
|
2014-10-03 |
2021-05-12 |
コールド スプリング ハーバー ラボラトリー |
核内遺伝子出力の標的とされた増強
|
CA2966044A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
EP3271460A4
(en)
|
2015-03-17 |
2019-03-13 |
The General Hospital Corporation |
INTERACTOME RNA OF COMPLEX REPRESSIVE POLYCOMB 1 (PRC1)
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
US10196639B2
(en)
|
2015-10-09 |
2019-02-05 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
US11136584B2
(en)
|
2015-11-04 |
2021-10-05 |
Duke University |
Splice-switching oligonucleotides and methods of use
|
AU2016366694C1
(en)
|
2015-12-10 |
2021-03-25 |
Ptc Therapeutics, Inc. |
Methods for treating huntington's disease
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
US11083745B2
(en)
|
2015-12-14 |
2021-08-10 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
|
JOP20200228A1
(ar)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
تركيبات وطرق لخفض تعبير البروتين tau
|
CN107338250B
(zh)
*
|
2016-05-03 |
2021-01-26 |
台中荣民总医院 |
对突变型多巴脱羧酶基因做剪接调整的反义寡核苷酸及其使用方法
|
EP3471779A4
(en)
|
2016-06-16 |
2020-07-08 |
Ionis Pharmaceuticals, Inc. |
COMBINATIONS FOR MODULATING THE SMN EXPRESSION
|
EP3478697A1
(en)
|
2016-06-30 |
2019-05-08 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystrophy
|
MX2019006882A
(es)
|
2016-12-19 |
2019-08-16 |
Sarepta Therapeutics Inc |
Conjugados de oligomeros de omision de exon para distrofia muscular.
|
NZ755422A
(en)
|
2016-12-19 |
2023-06-30 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
MD3554552T2
(ro)
|
2016-12-19 |
2022-12-31 |
Sarepta Therapeutics Inc |
Conjugați oligomeri de omitere a exonilor pentru distrofie musculară
|
EP3594346A4
(en)
*
|
2017-03-10 |
2020-12-16 |
National Center For Child Health And Development |
ANTISENSE OLIGONUCLEOTIDE AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA
|
KR20200033249A
(ko)
|
2017-06-05 |
2020-03-27 |
피티씨 테라퓨틱스, 인크. |
헌팅턴병 치료 화합물
|
MX2019015580A
(es)
|
2017-06-28 |
2020-07-28 |
Ptc Therapeutics Inc |
Metodos para tratar la enfermedad de huntington.
|
MX2019015578A
(es)
|
2017-06-28 |
2020-07-28 |
Ptc Therapeutics Inc |
Metodos para tratar la enfermedad de huntington.
|
GB2594767B
(en)
|
2017-08-25 |
2022-06-22 |
Stoke Therapeutics Inc |
Antisense oligomers for treatment of conditions and diseases
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
JP6884268B2
(ja)
*
|
2018-03-09 |
2021-06-09 |
第一三共株式会社 |
糖原病Ia型治療薬
|
US11866689B2
(en)
|
2018-03-26 |
2024-01-09 |
Duke University |
Splice-switching oligonucleotides and methods of use
|
JP7399870B2
(ja)
|
2018-03-27 |
2023-12-18 |
ピーティーシー セラピューティクス, インコーポレイテッド |
ハンチントン病を処置するための化合物
|
US10758629B2
(en)
|
2018-05-29 |
2020-09-01 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
DK3814357T3
(da)
|
2018-06-27 |
2024-07-22 |
Ptc Therapeutics Inc |
Heterocykliske og heteroarylforbindelser til behandling af huntingtons sygdom
|
US20220154182A1
(en)
|
2019-03-20 |
2022-05-19 |
President And Fellows Of Harvard College |
Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
CN112111528B
(zh)
*
|
2019-06-21 |
2024-04-02 |
华东师范大学 |
一种内含子异常剪接的修复方法
|
EP4051280A1
(en)
|
2019-11-01 |
2022-09-07 |
Novartis AG |
The use of a splicing modulator for a treatment slowing progression of huntington's disease
|
JPWO2021112106A1
(fi)
*
|
2019-12-02 |
2021-06-10 |
|
|
IL295605A
(en)
|
2020-02-28 |
2022-10-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating smn2
|
JP2023525799A
(ja)
|
2020-05-11 |
2023-06-19 |
ストーク セラピューティクス,インク. |
状態及び疾患の治療のためのopa1アンチセンスオリゴマー
|
TW202304446A
(zh)
|
2021-03-29 |
2023-02-01 |
瑞士商諾華公司 |
剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
|
WO2022241408A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating tissue distribution of intracellular therapeutics
|